Clinical Takeaway
In a controlled crossover trial of healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability compared to placebo. This suggests CBD may not have direct intrinsic anti-epileptic effects on its own, and its clinical benefit in seizure disorders like Dravet syndrome likely depends on its pharmacokinetic interaction with clobazam rather than independent brain activity. Patients and clinicians should understand that CBD’s seizure-reducing effects in these conditions are probably not a standalone action on the brain.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may depend primarily on pharmacokinetic interactions with concomitant medications rather than direct effects on neuronal excitability, which has significant implications for dosing strategies and drug combination selection in epilepsy management. The finding that CBD lacks direct cortical excitability effects challenges assumptions about its mechanism of action and suggests that seizure control achieved with CBD-clobazam combinations may be attributable to altered metabolism of clobazam rather than CBD’s independent anti-seizure properties. These results are critical for optimizing polypharmacy regimens in Dravet and Lennox-Gastaut syndromes and for understanding when CBD monotherapy
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover study challenges a common assumption in cannabis medicine by demonstrating that CBD alone does not directly suppress cortical excitability in humans, suggesting its clinical efficacy in seizure disorders may depend primarily on pharmacokinetic interactions with concurrent medications like clobazam rather than independent anti-epileptic properties. While this finding is methodologically sound, it’s important to acknowledge that the study population, dosing regimen, and measurement techniques may not capture all mechanisms by which CBD influences seizure control in real-world practice, particularly in patients with genetic epilepsies who may have distinct neurobiological responses. Additionally, the lack of direct cortical effects does not preclude CBD’s benefits through other pathways such as anti-inflammatory, anxiolytic, or gut microbiome-mediated mechanisms that could still contribute clinically. For practitioners, this research suggests that when prescribing CBD for seizure management, careful attention to drug interactions and baseline ASM regimens is essential, and standalone CBD therapy for seizure disorders should